New Facility

The investment will expand production capacity, meet growing demand and strengthen supply resilience in growing feed markets.

The site is the company’s first ground-up factory in more than 50 years.

The solar-powered, off-grid facility can store about 40 million vaccine doses, helping protect them from power outages.

The site expansion bolsters Elanco’s monoclonal antibody (mAb) production; supports delivery of next-generation pipeline.

The project will repurpose a 463,503-square-foot fermentation facility at ADM’s Clinton complex.

The facility is expected to open by the end of 2026.

The facility is expected to produce approximately 20 to 30 tonnes of giant grouper annually.

A further 14 facilities are at various stages of completion across the country, strengthening livestock health.

The integration is expected to be completed by early 2027.

The Greenock facility is expected to become operational later this year.